上海透景生命科技股份有限公司（300642）2025年年度报告深度解读

一、报告亮点与关键信息

• 核心业务：公司专注于自主品牌体外诊断（IVD）产品的研发、生产与销售，广泛覆盖肿瘤全病程检测、自身免疫、激素、心血管疾病、病原体感染及生殖健康等领域。产品已覆盖全国31个省市，并积极拓展海外市场。
• 技术平台：公司拥有高通量荧光技术、化学发光免疫分析、多重多色荧光PCR、快速FISH等多平台技术，形成“流式荧光+PCR+FISH”多维技术布局。
• 产品线丰富：累计获得607个国内医疗器械注册及备案证书，200余个产品通过CE自我声明，部分产品已进入东南亚等市场。
• 并购扩张：2025年收购武汉康录生物控股权，快速进入分子病理及FISH检测领域，完善肿瘤全病程管理产品线。
• 细分领域布局：肿瘤标志物种类齐全，HPV核酸检测产品分型细致，国内首个肺癌甲基化检测产品落地，拓展自身免疫、真菌感染等市场。
• 营销网络：经销为主、直销为辅，覆盖全国，采用“仪器+试剂”联动销售模式，并积极开展医学检验服务。
• 海外发展：持续推进海外团队组建及产品准入，与康录生物海外团队合作，加快国际市场推广。

二、对股东及潜在投资者的重要影响事项

• 业绩下滑与集采冲击：2025年公司营业收入为3.64亿元，同比下降16.70%；归母净利润仅358.79万元，同比大降89.61%。肿瘤标志物与HPV产品全面纳入集采，使两项核心产品价格和毛利承压，成为业绩下降主因。这一变化对公司短期盈利能力影响极大，具有高度价格敏感性。
• 降本增效与产品转型：公司积极采取降本增效措施，并加速研发非集采、技术壁垒高的新产品，同时通过并购补齐真菌检测、分子病理等高成长赛道。
• 研发持续投入：2025年研发投入5846.31万元，占营收16.07%。多项新产品获批，包括宫颈癌初筛/分流HPV检测、十五项自身免疫肌炎抗体谱、8个单指标自免检测产品，显示公司创新能力及未来成长潜力。
• 并购整合成效显现：成功整合河北透景和康录生物，补齐了侵袭性真菌病检测及分子病理板块。康录生物新获产前染色体FISH检测试剂盒注册证，开拓生殖健康及优生优育市场。
• 政策风险与行业机遇并存：体外诊断行业进入集采、医保控费、检验结果互认等政策密集调整期，短期内对价格和销量产生压力。然而，国产替代进程加速，对技术领先的国产企业是长期利好。
• 持续高分红与股东回报：2024年向全体股东分红2416.14万元，公司累计分红达2.64亿元，分红率突出，体现对投资者回报重视。
• 激励与回购：2025年公司以2002.69万元自有资金回购股份，用于股权激励，显示管理层对公司未来发展信心。
• 财务状况稳健：2025年末总资产20.57亿元，同比增长17.60%；经营现金流净额1.43亿元，具备良好运营能力。

三、详细经营与财务数据解读

• 主要财务指标变化：
  • 2025年营业收入3.64亿元，较2024年下降16.70%；其中试剂收入3.47亿元，占比95.24%，同比下降15.75%。
  • 归母净利润358.79万元，同比锐减89.61%；扣非净利润为-588.26万元，首次转为亏损。
  • 经销端收入降幅（-14.80%）明显优于直销端（-21.74%），医院客户受集采影响小于第三方检测/体检客户。
  • 资产总额20.57亿元，净资产14.26亿元，资产负债结构健康。
  • 毛利率承压，净资产收益率仅0.24%，远低于往年水平。
• 研发与新产品成果：
  • HPV核酸检测产品获批新的临床应用场景，覆盖宫颈癌初筛、分流，强化终端适应性。
  • 自身免疫检测产品持续扩充，获批数字化定量解读肌炎抗体谱新品，满足多层次临床需求。
  • 并购康录生物后，FISH产前染色体检测产品获证，为生殖健康方向提供新增长点。
• 营销与海外拓展：
  • 完善营销队伍，优化销售结构，提升整体战斗力。
  • 加强海外市场准入与推广，与康录生物团队协同拓展国际业务。
• 行业与政策环境：
  • 体外诊断产业年复合增长率高于全球平均，国产替代趋势明显。
  • 集采、医保控费、检验结果互认等政策加速行业洗牌，企业需加速技术创新与市场应变。
  • 公司凭借高性价比和本土化优势，在肿瘤、自免、心脏、分子病理等领域具备领先地位。

四、可能影响股价的重要信息

• 重大利空：肿瘤标志物和HPV产品全面被纳入集采，2025年业绩大幅下滑，短期内盈利能力承压，或对公司股价形成压力。
• 潜在利好：公司通过并购快速补齐产品短板，技术平台多元化，研发投入高，未来有望依靠新产品和海外市场实现业绩恢复与增长。
• 股东回报持续性：持续高分红和股份回购体现对投资者高度负责，增强市场信心。

五、结论

综上所述，上海透景生命科技股份有限公司在2025年面临集采政策带来的巨大业绩压力，但公司通过并购、持续研发、完善产品矩阵及海外拓展等举措，为中长期发展奠定坚实基础。短期内业绩承压或影响股价表现，但中长期成长逻辑未变，具备技术和产品壁垒的细分龙头有望在行业调整中脱颖而出。投资者应关注公司新产品放量、集采压力化解和海外市场突破等关键变量的进展。

免责声明

本文仅供投资参考，不构成任何投资建议。投资者据此操作，风险自负。请密切关注公司后续公告及行业政策变化。

English Version

Shanghai Tellgen Life Technology (300642) 2025 Annual Report: Detailed Investor Review

1. Highlights and Key Information

• Core Business: Focus on self-owned brand in vitro diagnostic (IVD) product R&D, production, and sales, covering tumor detection, autoimmune, hormones, cardiovascular, pathogen infection, reproductive health, and more. Nationwide coverage (31 provinces), active overseas expansion.
• Technology Platform: Holds multi-dimensional technology platforms: high-throughput fluorescence, chemiluminescence immunoassay, multiplex fluorescence PCR, rapid FISH, forming a “flow fluorescence + PCR + FISH” layout.
• Diversified Product Line: 607 domestic registrations/filings, 200+ products CE-marked, with entries into Southeast Asia and other markets.
• Acquisition Expansion: In 2025, acquired Wuhan Kanglu Bio, rapidly entering molecular pathology and FISH testing, completing full tumor management product matrix.
• Segmented Market Focus: Complete tumor marker panel, advanced HPV nucleic acid detection, first domestic lung cancer methylation test, expansion into autoimmune and fungal infection diagnostics.
• Marketing Network: Distribution-based, supplemented by direct sales, nationwide coverage, “instrument + reagent” model, and active medical laboratory services.
• Overseas Development: Accelerated team building and product registration for overseas markets, collaborating with Kanglu Bio’s team for international expansion.

2. Key Issues for Shareholders and Investors

• Performance Decline Due to Centralized Procurement: 2025 revenue of RMB 364 million (-16.7% YoY), net profit attributable to parent RMB 3.59 million (-89.61% YoY). Tumor marker and HPV products fully included in centralized procurement, core product margins under pressure—a significant, price-sensitive event.
• Cost Reduction & Product Transformation: Company is accelerating cost reductions, focusing on non-procurement, high-tech new products, and filling blanks in fungal and molecular pathology diagnostics through acquisitions.
• R&D Investment: Spent RMB 58.46 million (16.07% of revenue) in 2025. Multiple new products approved, including HPV tests for cervical cancer, autoimmune myositis antibody panels, and eight single-indicator autoimmune products, showing innovation and future growth potential.
• Acquisition Integration Results: Integrated Hebei Tellgen (fungal diagnostics) and Kanglu Bio (molecular pathology leader), the latter obtaining FISH-based prenatal chromosomal tests, expanding into reproductive health.
• Policy Risks & Industry Opportunities: IVD industry faces centralized procurement, cost controls, and result recognition. Short-term pressure on price/volume, but domestic substitution accelerates, benefiting leading Chinese firms in the long run.
• Shareholder Returns: High dividend payout (RMB 24.16 million in 2024, cumulative RMB 264 million), 52.98% of IPO proceeds, showing strong commitment to investor returns.
• Incentive & Buyback: RMB 20 million share buyback for incentives, signaling management’s confidence in the company’s future.
• Financial Stability: Total assets RMB 2.06 billion (+17.6% YoY), operating cash flow RMB 143 million, solid financials.

3. Detailed Business & Financial Analysis

• Key Financial Changes:
  • 2025 revenue RMB 364 million, down 16.7% YoY; reagent sales RMB 347 million, 95.24% of total, down 15.75% YoY.
  • Net profit attributable to parent RMB 3.59 million, down 89.61% YoY; non-recurring loss RMB -5.88 million, turning negative for the first time.
  • Distributor-end revenue decline (-14.80%) less severe than direct sales (-21.74%); hospital clients less impacted than third-party/physical exam clients.
  • Total assets RMB 2.06 billion, net assets RMB 1.43 billion, healthy structure.
  • Gross margin and ROE under pressure: only 0.24% in 2025.
• R&D and Product Progress:
  • HPV products approved for broader clinical scenarios, strengthening market fit.
  • Autoimmune test line expanded, gaining digital myositis antibody spectrum test approval, meeting multi-level clinical demand.
  • Acquired Kanglu Bio, whose FISH prenatal chromosome product supports reproductive health business growth.
• Marketing & Overseas Expansion:
  • Upgraded sales team and structure for improved effectiveness.
  • Accelerated overseas registration and marketing, working with Kanglu Bio’s international team.
• Industry & Policy Landscape:
  • China’s IVD market growing faster than the global average; import substitution trend clear.
  • Procurement, cost control, and mutual test result recognition policies drive industry reshuffle; firms must innovate and adapt quickly.
  • Company is a leader in oncology, autoimmune, cardiovascular, and molecular pathology sectors.

4. Price-Sensitive Information

• Major Negative: Tumor marker and HPV reagent products fully included in centralized procurement; 2025 performance drops sharply, short-term profit under pressure—potential negative for share price.
• Potential Positives: Fast product line expansion via acquisition, diversified technology, high R&D investment—future growth may come from new products and overseas markets.
• Shareholder Returns: Continued high dividends and buybacks demonstrate strong commitment to investor value.

5. Conclusion

In summary, Shanghai Tellgen Life Technology faces significant short-term earnings pressure from centralized procurement policy, but its ongoing M&A, R&D, product matrix improvement, and overseas expansion lay a solid foundation for long-term growth. The company remains a technical and product leader in its segment and, over the longer term, is well positioned to benefit from the domestic substitution trend. Investors should monitor new product ramp-ups, margin recovery, and overseas breakthroughs.

Disclaimer

The information above is for reference only and does not constitute investment advice. Investors should act at their own risk and closely monitor company disclosures and industry policies.

View 透景生命 Historical chart here